Matthew Beyersdorf

Matthew Beyersdorf, PhD

Associate | Biotechnology
617.646.8258 LinkedIn Profile


  • BS, Biology, University of North Carolina Wilmington
  • BA, Chemistry, University of North Carolina Wilmington
  • MS, Chemistry, University of North Carolina Wilmington
  • PhD, Chemical Biology, University of Michigan
  • JD, Suffolk University Law School

Key Technologies

  • Molecular and Cellular Biology
  • Cell-based Therapies
  • Gene Editing Tools and Techniques
  • Drug Development
  • Drug Formulations and Delivery
  • RNA Therapeutics (mRNA, Antisense)
  • Modulation of the Microbiome

Practice Groups

Admitted to Practice

  • District of Columbia
  • US Patent and Trademark Office


  • Washington, DC


Matthew Beyersdorf focuses his practice on patent prosecution and counseling in the life sciences sector with a particular focus on molecular biology, gene editing, cellular biology, drug development, and genetics.

Matthew helps a diverse array of clients including early-stage companies, multinational corporations, and research institutions protect their innovations in the US and internationally. He has extensive experience with patent drafting, patent prosecution, due diligence, IP portfolio management, and freedom-to-operate analyses.

Prior to joining Wolf Greenfield, Matthew earned a doctorate in Chemical Biology at the University of Michigan, where his thesis research centered on the discovery of natural products and organic small molecules that modulate transcriptional protein-protein interactions involved in cancer progression. During this time, he was involved in high-throughput screening efforts of a natural products library, developed NMR methods for studying protein-protein interactions, utilized process chemistry approaches to produce large-scale quantities of microbial secondary metabolites, proteins and synthetic peptides, and studied the effects of organic small molecules in human cancer cells using cellular reporter assays.

Additionally, Matthew was a Project Manager and the Director of Public Relations at miLEAD Consulting Group, a non-profit consulting firm that provides short-term services to scientists and technology companies in Southeast Michigan.


  • Prepared and prosecuted patent applications in the areas of antibody therapeutics, TCR Treg therapy, methods of genome editing, nucleic acid-based therapeutics, methods of RNA production, pesticide compositions and associated methods (including RNA-based pesticide compositions), and microbiome modulation
  • Developed patent portfolios and long-term patent strategy for early-stage companies involved in antibody therapeutics, TCR Treg therapy, gut microbiome modulation, and vaginal microbiome modulation
  • Obtained issued patents that protect commercial products, including pharmaceutical compositions that have undergone clinical trials in the US and Europe
  • Conducted freedom-to-operate studies for an industrial client in advance of filing Investigational New Drug applications
  • Assisted in conducting a broad evaluation of a company’s IP portfolio in order to assist with re-structuring their ongoing IP strategy
  • Conducted due diligence studies on patent landscape and market exclusivity in connection with anticipated biotechnology acquisition


  • US Dept. of Education GAANN Fellow, University of Michigan


Scientific Publications

  • Breen ME, Joy ST, Baruti OJ, Beyersdorf MS, Henley MJ, De Salle SN, Ycas PD, Croskey A, Cierpicki T, Pomerantz WCK, Mapp AK. Garcinolic Acid Distinguishes Between GACKIX Domains and Modulates Interaction Networks. Chembiochem. 2023 Nov 2;24(21):e202300439. doi: 10.1002/cbic.202300439.
  • Pattelli ON, Valdivia EM, Beyersdorf MS, Regan CS, Rivas M, Merajver SD, Cierpicki T, Mapp AK. A lipopeptidomimetic of transcriptional activation domains selectively disrupts Med25 PPIs. bioRxiv. 2023 Mar 25:2023.03.24.534168. doi: 10.1101/2023.03.24.534168. Preprint.
  • Joy ST, Henley MJ, De Salle SN, Beyersdorf MS, Vock IW, Huldin AJL, Mapp AK. A Dual-Site Inhibitor of CBP/p300 KIX is a Selective and Effective Modulator of Myb. J Am Chem Soc. 2021 Sep 22;143(37):15056-15062.
  • Henderson AR, Henley MJ, Foster NJ, Peiffer AL, Beyersdorf MS, Stanford KD, Sturlis SM, Linhares BM, Hill ZB, Wells JA, Cierpicki T, Brooks CL 3rd, Fierke CA, Mapp AK. Conservation of coactivator engagement mechanism enables small-molecule allosteric modulators. Proc Natl Acad Sci U S A. 2018;115(36):8960-8965.
  • Lookadoo DB, Beyersdorf MS, Halkides CJ. Synthesis of a Stable Analog of the Phosphorylated Form of CheY: Phosphono-CheY. Methods in Molecular Biology 2018;1729:337-343.
  • Beyersdorf MS, Sircar R, Lookadoo DB, Bottone CJ, Lynch MJ, Crane BR, Halkides CJ. Production, characterization, and assessment of a stable analog of the response regulator CheY-phosphate from Thermotoga maritima. Protein Science. 2017 Aug;26(8):1547-1554.
  • Sircar R, Borbat PP, Lynch MJ, Bhatnagar J, Beyersdorf MS, Halkides CJ, Freed JH, Crane BR. Assembly states of FliM and FliG within the flagellar switch complex. J. Molecular Biology 2015 Feb 27;427(4):867-86.


Matt enjoys exploring parks and running around with his two young kids, spending time in the kitchen, and watching the latest prestige television show.